nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydromorphone—Levorphanol—Estrone—prostate cancer	0.195	0.569	CrCrCtD
Hydromorphone—Levorphanol—Estradiol—prostate cancer	0.148	0.431	CrCrCtD
Hydromorphone—CYP3A4—prostate cancer	0.104	1	CbGaD
Hydromorphone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0299	0.0995	CbGbCtD
Hydromorphone—CYP2C9—Nilutamide—prostate cancer	0.027	0.0899	CbGbCtD
Hydromorphone—CYP2C9—Bicalutamide—prostate cancer	0.027	0.0899	CbGbCtD
Hydromorphone—CYP2D6—Bicalutamide—prostate cancer	0.0247	0.0822	CbGbCtD
Hydromorphone—CYP2D6—Abiraterone—prostate cancer	0.0205	0.0681	CbGbCtD
Hydromorphone—CYP2C9—Estrone—prostate cancer	0.0162	0.0539	CbGbCtD
Hydromorphone—CYP3A4—Bicalutamide—prostate cancer	0.0157	0.0523	CbGbCtD
Hydromorphone—PTGS1—Etoposide—prostate cancer	0.0151	0.0502	CbGbCtD
Hydromorphone—CYP3A4—Estramustine—prostate cancer	0.0146	0.0486	CbGbCtD
Hydromorphone—CYP3A4—Flutamide—prostate cancer	0.013	0.0433	CbGbCtD
Hydromorphone—CYP3A4—Abiraterone—prostate cancer	0.013	0.0433	CbGbCtD
Hydromorphone—CYP2C9—Capecitabine—prostate cancer	0.0123	0.0408	CbGbCtD
Hydromorphone—CYP3A4—Cabazitaxel—prostate cancer	0.00964	0.032	CbGbCtD
Hydromorphone—CYP3A4—Estrone—prostate cancer	0.00942	0.0313	CbGbCtD
Hydromorphone—CYP2C9—Estradiol—prostate cancer	0.0093	0.0309	CbGbCtD
Hydromorphone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0084	0.0279	CbGbCtD
Hydromorphone—CYP3A4—Conjugated Estrogens—prostate cancer	0.00616	0.0205	CbGbCtD
Hydromorphone—CYP3A4—Mitoxantrone—prostate cancer	0.0056	0.0186	CbGbCtD
Hydromorphone—CYP3A4—Estradiol—prostate cancer	0.00541	0.018	CbGbCtD
Hydromorphone—CYP3A4—Prednisone—prostate cancer	0.00465	0.0155	CbGbCtD
Hydromorphone—CYP2D6—Doxorubicin—prostate cancer	0.00379	0.0126	CbGbCtD
Hydromorphone—CYP3A4—Etoposide—prostate cancer	0.00353	0.0117	CbGbCtD
Hydromorphone—CYP3A4—Docetaxel—prostate cancer	0.00323	0.0107	CbGbCtD
Hydromorphone—CYP3A4—Doxorubicin—prostate cancer	0.00241	0.00801	CbGbCtD
Hydromorphone—Dextromethorphan—PGRMC1—prostate cancer	0.000849	0.238	CrCbGaD
Hydromorphone—CYP2C9—urine—prostate cancer	0.000846	0.141	CbGeAlD
Hydromorphone—OPRK1—prostate gland—prostate cancer	0.000799	0.133	CbGeAlD
Hydromorphone—UGT1A9—renal system—prostate cancer	0.000719	0.12	CbGeAlD
Hydromorphone—CYP3A4—urine—prostate cancer	0.000645	0.108	CbGeAlD
Hydromorphone—CYP2D6—urine—prostate cancer	0.000635	0.106	CbGeAlD
Hydromorphone—Morphine—UGT2B15—prostate cancer	0.000612	0.172	CrCbGaD
Hydromorphone—OPRD1—renal system—prostate cancer	0.000568	0.0948	CbGeAlD
Hydromorphone—Naloxone—TLR4—prostate cancer	0.000477	0.134	CrCbGaD
Hydromorphone—PTGS1—prostate gland—prostate cancer	0.000277	0.0463	CbGeAlD
Hydromorphone—OPRM1—testis—prostate cancer	0.00025	0.0418	CbGeAlD
Hydromorphone—PTGS1—seminal vesicle—prostate cancer	0.000235	0.0391	CbGeAlD
Hydromorphone—Codeine—SLC22A1—prostate cancer	0.000204	0.0571	CrCbGaD
Hydromorphone—PTGS1—epithelium—prostate cancer	0.000204	0.034	CbGeAlD
Hydromorphone—PTGS1—renal system—prostate cancer	0.000189	0.0315	CbGeAlD
Hydromorphone—Oxycodone—CYP3A5—prostate cancer	0.000172	0.0483	CrCbGaD
Hydromorphone—Codeine—CYP3A5—prostate cancer	0.000164	0.0461	CrCbGaD
Hydromorphone—CYP3A4—renal system—prostate cancer	0.000158	0.0264	CbGeAlD
Hydromorphone—CYP2D6—renal system—prostate cancer	0.000155	0.0259	CbGeAlD
Hydromorphone—Naloxone—ESR1—prostate cancer	0.000134	0.0375	CrCbGaD
Hydromorphone—PTGS1—testis—prostate cancer	0.000122	0.0204	CbGeAlD
Hydromorphone—Dextromethorphan—CYP3A5—prostate cancer	0.000112	0.0313	CrCbGaD
Hydromorphone—Dihydrocodeine—CYP3A4—prostate cancer	0.000107	0.0299	CrCbGaD
Hydromorphone—CYP2D6—testis—prostate cancer	0.0001	0.0168	CbGeAlD
Hydromorphone—Oxymorphone—CYP3A4—prostate cancer	9.35e-05	0.0262	CrCbGaD
Hydromorphone—Ethylmorphine—CYP3A4—prostate cancer	8.94e-05	0.0251	CrCbGaD
Hydromorphone—PTGS1—lymph node—prostate cancer	8.85e-05	0.0148	CbGeAlD
Hydromorphone—Hydrocodone—CYP3A4—prostate cancer	8.18e-05	0.0229	CrCbGaD
Hydromorphone—Dextromethorphan—CYP2E1—prostate cancer	7.68e-05	0.0215	CrCbGaD
Hydromorphone—Dextromethorphan—CYP2C19—prostate cancer	7.61e-05	0.0213	CrCbGaD
Hydromorphone—Oxycodone—CYP3A4—prostate cancer	7.46e-05	0.0209	CrCbGaD
Hydromorphone—Codeine—CYP3A4—prostate cancer	7.12e-05	0.0199	CrCbGaD
Hydromorphone—Naloxone—CYP3A4—prostate cancer	6.82e-05	0.0191	CrCbGaD
Hydromorphone—Morphine—CYP3A4—prostate cancer	5.76e-05	0.0161	CrCbGaD
Hydromorphone—Dextromethorphan—CYP3A4—prostate cancer	4.84e-05	0.0136	CrCbGaD
Hydromorphone—Hypotension—Capecitabine—prostate cancer	3e-05	0.000197	CcSEcCtD
Hydromorphone—Insomnia—Docetaxel—prostate cancer	3e-05	0.000197	CcSEcCtD
Hydromorphone—Myalgia—Prednisone—prostate cancer	2.98e-05	0.000196	CcSEcCtD
Hydromorphone—Arthralgia—Prednisone—prostate cancer	2.98e-05	0.000196	CcSEcCtD
Hydromorphone—Paraesthesia—Docetaxel—prostate cancer	2.98e-05	0.000196	CcSEcCtD
Hydromorphone—Anxiety—Prednisone—prostate cancer	2.97e-05	0.000195	CcSEcCtD
Hydromorphone—Bradycardia—Doxorubicin—prostate cancer	2.96e-05	0.000195	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.96e-05	0.000195	CcSEcCtD
Hydromorphone—Dyspnoea—Docetaxel—prostate cancer	2.95e-05	0.000194	CcSEcCtD
Hydromorphone—Somnolence—Docetaxel—prostate cancer	2.95e-05	0.000194	CcSEcCtD
Hydromorphone—Discomfort—Prednisone—prostate cancer	2.95e-05	0.000194	CcSEcCtD
Hydromorphone—Eye disorder—Epirubicin—prostate cancer	2.94e-05	0.000193	CcSEcCtD
Hydromorphone—Hypersensitivity—Etoposide—prostate cancer	2.94e-05	0.000193	CcSEcCtD
Hydromorphone—Tinnitus—Epirubicin—prostate cancer	2.93e-05	0.000193	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.92e-05	0.000192	CcSEcCtD
Hydromorphone—Flushing—Epirubicin—prostate cancer	2.92e-05	0.000192	CcSEcCtD
Hydromorphone—Cardiac disorder—Epirubicin—prostate cancer	2.92e-05	0.000192	CcSEcCtD
Hydromorphone—Rhinitis—Doxorubicin—prostate cancer	2.92e-05	0.000192	CcSEcCtD
Hydromorphone—Dyspepsia—Docetaxel—prostate cancer	2.92e-05	0.000192	CcSEcCtD
Hydromorphone—Insomnia—Capecitabine—prostate cancer	2.9e-05	0.000191	CcSEcCtD
Hydromorphone—Hypoaesthesia—Doxorubicin—prostate cancer	2.9e-05	0.000191	CcSEcCtD
Hydromorphone—Paraesthesia—Capecitabine—prostate cancer	2.88e-05	0.000189	CcSEcCtD
Hydromorphone—Decreased appetite—Docetaxel—prostate cancer	2.88e-05	0.000189	CcSEcCtD
Hydromorphone—Urinary tract disorder—Doxorubicin—prostate cancer	2.87e-05	0.000189	CcSEcCtD
Hydromorphone—Oedema peripheral—Doxorubicin—prostate cancer	2.87e-05	0.000189	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Docetaxel—prostate cancer	2.86e-05	0.000188	CcSEcCtD
Hydromorphone—Asthenia—Etoposide—prostate cancer	2.86e-05	0.000188	CcSEcCtD
Hydromorphone—Connective tissue disorder—Doxorubicin—prostate cancer	2.86e-05	0.000188	CcSEcCtD
Hydromorphone—Dyspnoea—Capecitabine—prostate cancer	2.86e-05	0.000188	CcSEcCtD
Hydromorphone—Anaphylactic shock—Prednisone—prostate cancer	2.86e-05	0.000188	CcSEcCtD
Hydromorphone—Fatigue—Docetaxel—prostate cancer	2.86e-05	0.000188	CcSEcCtD
Hydromorphone—Angiopathy—Epirubicin—prostate cancer	2.85e-05	0.000188	CcSEcCtD
Hydromorphone—Urethral disorder—Doxorubicin—prostate cancer	2.85e-05	0.000188	CcSEcCtD
Hydromorphone—Nausea—Mitoxantrone—prostate cancer	2.85e-05	0.000187	CcSEcCtD
Hydromorphone—Immune system disorder—Epirubicin—prostate cancer	2.84e-05	0.000187	CcSEcCtD
Hydromorphone—Infection—Prednisone—prostate cancer	2.84e-05	0.000187	CcSEcCtD
Hydromorphone—Mediastinal disorder—Epirubicin—prostate cancer	2.84e-05	0.000186	CcSEcCtD
Hydromorphone—Constipation—Docetaxel—prostate cancer	2.83e-05	0.000186	CcSEcCtD
Hydromorphone—Pain—Docetaxel—prostate cancer	2.83e-05	0.000186	CcSEcCtD
Hydromorphone—Dyspepsia—Capecitabine—prostate cancer	2.82e-05	0.000186	CcSEcCtD
Hydromorphone—Chills—Epirubicin—prostate cancer	2.82e-05	0.000186	CcSEcCtD
Hydromorphone—Pruritus—Etoposide—prostate cancer	2.82e-05	0.000186	CcSEcCtD
Hydromorphone—Shock—Prednisone—prostate cancer	2.81e-05	0.000185	CcSEcCtD
Hydromorphone—Arrhythmia—Epirubicin—prostate cancer	2.81e-05	0.000185	CcSEcCtD
Hydromorphone—Visual impairment—Doxorubicin—prostate cancer	2.81e-05	0.000185	CcSEcCtD
Hydromorphone—Nervous system disorder—Prednisone—prostate cancer	2.8e-05	0.000184	CcSEcCtD
Hydromorphone—Tachycardia—Prednisone—prostate cancer	2.79e-05	0.000183	CcSEcCtD
Hydromorphone—Decreased appetite—Capecitabine—prostate cancer	2.79e-05	0.000183	CcSEcCtD
Hydromorphone—Skin disorder—Prednisone—prostate cancer	2.78e-05	0.000183	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Capecitabine—prostate cancer	2.77e-05	0.000182	CcSEcCtD
Hydromorphone—Fatigue—Capecitabine—prostate cancer	2.77e-05	0.000182	CcSEcCtD
Hydromorphone—Hyperhidrosis—Prednisone—prostate cancer	2.76e-05	0.000182	CcSEcCtD
Hydromorphone—Mental disorder—Epirubicin—prostate cancer	2.76e-05	0.000181	CcSEcCtD
Hydromorphone—Pain—Capecitabine—prostate cancer	2.74e-05	0.00018	CcSEcCtD
Hydromorphone—Constipation—Capecitabine—prostate cancer	2.74e-05	0.00018	CcSEcCtD
Hydromorphone—Erythema—Epirubicin—prostate cancer	2.74e-05	0.00018	CcSEcCtD
Hydromorphone—Malnutrition—Epirubicin—prostate cancer	2.74e-05	0.00018	CcSEcCtD
Hydromorphone—Feeling abnormal—Docetaxel—prostate cancer	2.73e-05	0.00018	CcSEcCtD
Hydromorphone—Diarrhoea—Etoposide—prostate cancer	2.73e-05	0.000179	CcSEcCtD
Hydromorphone—Anorexia—Prednisone—prostate cancer	2.72e-05	0.000179	CcSEcCtD
Hydromorphone—Eye disorder—Doxorubicin—prostate cancer	2.72e-05	0.000179	CcSEcCtD
Hydromorphone—Tinnitus—Doxorubicin—prostate cancer	2.71e-05	0.000179	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Docetaxel—prostate cancer	2.71e-05	0.000178	CcSEcCtD
Hydromorphone—Flushing—Doxorubicin—prostate cancer	2.7e-05	0.000178	CcSEcCtD
Hydromorphone—Cardiac disorder—Doxorubicin—prostate cancer	2.7e-05	0.000178	CcSEcCtD
Hydromorphone—Flatulence—Epirubicin—prostate cancer	2.7e-05	0.000177	CcSEcCtD
Hydromorphone—Tension—Epirubicin—prostate cancer	2.69e-05	0.000177	CcSEcCtD
Hydromorphone—Dysgeusia—Epirubicin—prostate cancer	2.68e-05	0.000176	CcSEcCtD
Hydromorphone—Nervousness—Epirubicin—prostate cancer	2.66e-05	0.000175	CcSEcCtD
Hydromorphone—Back pain—Epirubicin—prostate cancer	2.65e-05	0.000174	CcSEcCtD
Hydromorphone—Feeling abnormal—Capecitabine—prostate cancer	2.64e-05	0.000174	CcSEcCtD
Hydromorphone—Angiopathy—Doxorubicin—prostate cancer	2.64e-05	0.000174	CcSEcCtD
Hydromorphone—Dizziness—Etoposide—prostate cancer	2.64e-05	0.000173	CcSEcCtD
Hydromorphone—Muscle spasms—Epirubicin—prostate cancer	2.63e-05	0.000173	CcSEcCtD
Hydromorphone—Immune system disorder—Doxorubicin—prostate cancer	2.63e-05	0.000173	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Capecitabine—prostate cancer	2.62e-05	0.000173	CcSEcCtD
Hydromorphone—Mediastinal disorder—Doxorubicin—prostate cancer	2.62e-05	0.000173	CcSEcCtD
Hydromorphone—Abdominal pain—Docetaxel—prostate cancer	2.62e-05	0.000172	CcSEcCtD
Hydromorphone—Body temperature increased—Docetaxel—prostate cancer	2.62e-05	0.000172	CcSEcCtD
Hydromorphone—Chills—Doxorubicin—prostate cancer	2.61e-05	0.000172	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Prednisone—prostate cancer	2.6e-05	0.000171	CcSEcCtD
Hydromorphone—Arrhythmia—Doxorubicin—prostate cancer	2.6e-05	0.000171	CcSEcCtD
Hydromorphone—Insomnia—Prednisone—prostate cancer	2.58e-05	0.00017	CcSEcCtD
Hydromorphone—Vision blurred—Epirubicin—prostate cancer	2.58e-05	0.00017	CcSEcCtD
Hydromorphone—Paraesthesia—Prednisone—prostate cancer	2.57e-05	0.000169	CcSEcCtD
Hydromorphone—Mental disorder—Doxorubicin—prostate cancer	2.55e-05	0.000168	CcSEcCtD
Hydromorphone—Urticaria—Capecitabine—prostate cancer	2.55e-05	0.000168	CcSEcCtD
Hydromorphone—Ill-defined disorder—Epirubicin—prostate cancer	2.54e-05	0.000167	CcSEcCtD
Hydromorphone—Abdominal pain—Capecitabine—prostate cancer	2.54e-05	0.000167	CcSEcCtD
Hydromorphone—Body temperature increased—Capecitabine—prostate cancer	2.54e-05	0.000167	CcSEcCtD
Hydromorphone—Vomiting—Etoposide—prostate cancer	2.54e-05	0.000167	CcSEcCtD
Hydromorphone—Malnutrition—Doxorubicin—prostate cancer	2.53e-05	0.000167	CcSEcCtD
Hydromorphone—Erythema—Doxorubicin—prostate cancer	2.53e-05	0.000167	CcSEcCtD
Hydromorphone—Agitation—Epirubicin—prostate cancer	2.52e-05	0.000166	CcSEcCtD
Hydromorphone—Dyspepsia—Prednisone—prostate cancer	2.52e-05	0.000165	CcSEcCtD
Hydromorphone—Rash—Etoposide—prostate cancer	2.51e-05	0.000165	CcSEcCtD
Hydromorphone—Dermatitis—Etoposide—prostate cancer	2.51e-05	0.000165	CcSEcCtD
Hydromorphone—Headache—Etoposide—prostate cancer	2.5e-05	0.000164	CcSEcCtD
Hydromorphone—Flatulence—Doxorubicin—prostate cancer	2.5e-05	0.000164	CcSEcCtD
Hydromorphone—Tension—Doxorubicin—prostate cancer	2.49e-05	0.000164	CcSEcCtD
Hydromorphone—Decreased appetite—Prednisone—prostate cancer	2.48e-05	0.000163	CcSEcCtD
Hydromorphone—Dysgeusia—Doxorubicin—prostate cancer	2.48e-05	0.000163	CcSEcCtD
Hydromorphone—Malaise—Epirubicin—prostate cancer	2.47e-05	0.000162	CcSEcCtD
Hydromorphone—Fatigue—Prednisone—prostate cancer	2.46e-05	0.000162	CcSEcCtD
Hydromorphone—Nervousness—Doxorubicin—prostate cancer	2.46e-05	0.000162	CcSEcCtD
Hydromorphone—Vertigo—Epirubicin—prostate cancer	2.46e-05	0.000162	CcSEcCtD
Hydromorphone—Syncope—Epirubicin—prostate cancer	2.46e-05	0.000162	CcSEcCtD
Hydromorphone—Leukopenia—Epirubicin—prostate cancer	2.45e-05	0.000161	CcSEcCtD
Hydromorphone—Back pain—Doxorubicin—prostate cancer	2.45e-05	0.000161	CcSEcCtD
Hydromorphone—Constipation—Prednisone—prostate cancer	2.44e-05	0.000161	CcSEcCtD
Hydromorphone—Hypersensitivity—Docetaxel—prostate cancer	2.44e-05	0.000161	CcSEcCtD
Hydromorphone—Muscle spasms—Doxorubicin—prostate cancer	2.44e-05	0.00016	CcSEcCtD
Hydromorphone—Palpitations—Epirubicin—prostate cancer	2.42e-05	0.000159	CcSEcCtD
Hydromorphone—Loss of consciousness—Epirubicin—prostate cancer	2.41e-05	0.000158	CcSEcCtD
Hydromorphone—Cough—Epirubicin—prostate cancer	2.39e-05	0.000157	CcSEcCtD
Hydromorphone—Vision blurred—Doxorubicin—prostate cancer	2.39e-05	0.000157	CcSEcCtD
Hydromorphone—Asthenia—Docetaxel—prostate cancer	2.38e-05	0.000156	CcSEcCtD
Hydromorphone—Convulsion—Epirubicin—prostate cancer	2.37e-05	0.000156	CcSEcCtD
Hydromorphone—Nausea—Etoposide—prostate cancer	2.37e-05	0.000156	CcSEcCtD
Hydromorphone—Hypertension—Epirubicin—prostate cancer	2.36e-05	0.000156	CcSEcCtD
Hydromorphone—Hypersensitivity—Capecitabine—prostate cancer	2.36e-05	0.000155	CcSEcCtD
Hydromorphone—Feeling abnormal—Prednisone—prostate cancer	2.36e-05	0.000155	CcSEcCtD
Hydromorphone—Ill-defined disorder—Doxorubicin—prostate cancer	2.35e-05	0.000155	CcSEcCtD
Hydromorphone—Pruritus—Docetaxel—prostate cancer	2.34e-05	0.000154	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Prednisone—prostate cancer	2.34e-05	0.000154	CcSEcCtD
Hydromorphone—Chest pain—Epirubicin—prostate cancer	2.33e-05	0.000153	CcSEcCtD
Hydromorphone—Arthralgia—Epirubicin—prostate cancer	2.33e-05	0.000153	CcSEcCtD
Hydromorphone—Myalgia—Epirubicin—prostate cancer	2.33e-05	0.000153	CcSEcCtD
Hydromorphone—Agitation—Doxorubicin—prostate cancer	2.33e-05	0.000153	CcSEcCtD
Hydromorphone—Anxiety—Epirubicin—prostate cancer	2.32e-05	0.000153	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.32e-05	0.000152	CcSEcCtD
Hydromorphone—Discomfort—Epirubicin—prostate cancer	2.3e-05	0.000152	CcSEcCtD
Hydromorphone—Asthenia—Capecitabine—prostate cancer	2.3e-05	0.000151	CcSEcCtD
Hydromorphone—Malaise—Doxorubicin—prostate cancer	2.29e-05	0.00015	CcSEcCtD
Hydromorphone—Dry mouth—Epirubicin—prostate cancer	2.28e-05	0.00015	CcSEcCtD
Hydromorphone—Vertigo—Doxorubicin—prostate cancer	2.28e-05	0.00015	CcSEcCtD
Hydromorphone—Syncope—Doxorubicin—prostate cancer	2.27e-05	0.000149	CcSEcCtD
Hydromorphone—Urticaria—Prednisone—prostate cancer	2.27e-05	0.000149	CcSEcCtD
Hydromorphone—Pruritus—Capecitabine—prostate cancer	2.27e-05	0.000149	CcSEcCtD
Hydromorphone—Leukopenia—Doxorubicin—prostate cancer	2.27e-05	0.000149	CcSEcCtD
Hydromorphone—Diarrhoea—Docetaxel—prostate cancer	2.27e-05	0.000149	CcSEcCtD
Hydromorphone—Abdominal pain—Prednisone—prostate cancer	2.26e-05	0.000149	CcSEcCtD
Hydromorphone—Body temperature increased—Prednisone—prostate cancer	2.26e-05	0.000149	CcSEcCtD
Hydromorphone—Confusional state—Epirubicin—prostate cancer	2.25e-05	0.000148	CcSEcCtD
Hydromorphone—Palpitations—Doxorubicin—prostate cancer	2.24e-05	0.000147	CcSEcCtD
Hydromorphone—Anaphylactic shock—Epirubicin—prostate cancer	2.24e-05	0.000147	CcSEcCtD
Hydromorphone—Loss of consciousness—Doxorubicin—prostate cancer	2.23e-05	0.000146	CcSEcCtD
Hydromorphone—Infection—Epirubicin—prostate cancer	2.22e-05	0.000146	CcSEcCtD
Hydromorphone—Cough—Doxorubicin—prostate cancer	2.21e-05	0.000145	CcSEcCtD
Hydromorphone—Shock—Epirubicin—prostate cancer	2.2e-05	0.000145	CcSEcCtD
Hydromorphone—Convulsion—Doxorubicin—prostate cancer	2.2e-05	0.000144	CcSEcCtD
Hydromorphone—Diarrhoea—Capecitabine—prostate cancer	2.2e-05	0.000144	CcSEcCtD
Hydromorphone—Nervous system disorder—Epirubicin—prostate cancer	2.19e-05	0.000144	CcSEcCtD
Hydromorphone—Dizziness—Docetaxel—prostate cancer	2.19e-05	0.000144	CcSEcCtD
Hydromorphone—Hypertension—Doxorubicin—prostate cancer	2.19e-05	0.000144	CcSEcCtD
Hydromorphone—Tachycardia—Epirubicin—prostate cancer	2.18e-05	0.000143	CcSEcCtD
Hydromorphone—Skin disorder—Epirubicin—prostate cancer	2.17e-05	0.000143	CcSEcCtD
Hydromorphone—Hyperhidrosis—Epirubicin—prostate cancer	2.16e-05	0.000142	CcSEcCtD
Hydromorphone—Chest pain—Doxorubicin—prostate cancer	2.16e-05	0.000142	CcSEcCtD
Hydromorphone—Arthralgia—Doxorubicin—prostate cancer	2.16e-05	0.000142	CcSEcCtD
Hydromorphone—Myalgia—Doxorubicin—prostate cancer	2.16e-05	0.000142	CcSEcCtD
Hydromorphone—Anxiety—Doxorubicin—prostate cancer	2.15e-05	0.000141	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.14e-05	0.000141	CcSEcCtD
Hydromorphone—Discomfort—Doxorubicin—prostate cancer	2.13e-05	0.00014	CcSEcCtD
Hydromorphone—Anorexia—Epirubicin—prostate cancer	2.13e-05	0.00014	CcSEcCtD
Hydromorphone—Dizziness—Capecitabine—prostate cancer	2.12e-05	0.00014	CcSEcCtD
Hydromorphone—Dry mouth—Doxorubicin—prostate cancer	2.11e-05	0.000139	CcSEcCtD
Hydromorphone—Vomiting—Docetaxel—prostate cancer	2.11e-05	0.000139	CcSEcCtD
Hydromorphone—Hypersensitivity—Prednisone—prostate cancer	2.11e-05	0.000138	CcSEcCtD
Hydromorphone—Rash—Docetaxel—prostate cancer	2.09e-05	0.000137	CcSEcCtD
Hydromorphone—Hypotension—Epirubicin—prostate cancer	2.09e-05	0.000137	CcSEcCtD
Hydromorphone—Dermatitis—Docetaxel—prostate cancer	2.09e-05	0.000137	CcSEcCtD
Hydromorphone—Confusional state—Doxorubicin—prostate cancer	2.09e-05	0.000137	CcSEcCtD
Hydromorphone—Headache—Docetaxel—prostate cancer	2.08e-05	0.000137	CcSEcCtD
Hydromorphone—Anaphylactic shock—Doxorubicin—prostate cancer	2.07e-05	0.000136	CcSEcCtD
Hydromorphone—Infection—Doxorubicin—prostate cancer	2.05e-05	0.000135	CcSEcCtD
Hydromorphone—Asthenia—Prednisone—prostate cancer	2.05e-05	0.000135	CcSEcCtD
Hydromorphone—Vomiting—Capecitabine—prostate cancer	2.04e-05	0.000134	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.04e-05	0.000134	CcSEcCtD
Hydromorphone—Shock—Doxorubicin—prostate cancer	2.03e-05	0.000134	CcSEcCtD
Hydromorphone—Nervous system disorder—Doxorubicin—prostate cancer	2.03e-05	0.000133	CcSEcCtD
Hydromorphone—Rash—Capecitabine—prostate cancer	2.02e-05	0.000133	CcSEcCtD
Hydromorphone—Pruritus—Prednisone—prostate cancer	2.02e-05	0.000133	CcSEcCtD
Hydromorphone—Insomnia—Epirubicin—prostate cancer	2.02e-05	0.000133	CcSEcCtD
Hydromorphone—Dermatitis—Capecitabine—prostate cancer	2.02e-05	0.000133	CcSEcCtD
Hydromorphone—Tachycardia—Doxorubicin—prostate cancer	2.02e-05	0.000133	CcSEcCtD
Hydromorphone—Headache—Capecitabine—prostate cancer	2.01e-05	0.000132	CcSEcCtD
Hydromorphone—Skin disorder—Doxorubicin—prostate cancer	2.01e-05	0.000132	CcSEcCtD
Hydromorphone—Paraesthesia—Epirubicin—prostate cancer	2.01e-05	0.000132	CcSEcCtD
Hydromorphone—Hyperhidrosis—Doxorubicin—prostate cancer	2e-05	0.000131	CcSEcCtD
Hydromorphone—Dyspnoea—Epirubicin—prostate cancer	1.99e-05	0.000131	CcSEcCtD
Hydromorphone—Somnolence—Epirubicin—prostate cancer	1.99e-05	0.000131	CcSEcCtD
Hydromorphone—Anorexia—Doxorubicin—prostate cancer	1.97e-05	0.00013	CcSEcCtD
Hydromorphone—Nausea—Docetaxel—prostate cancer	1.97e-05	0.000129	CcSEcCtD
Hydromorphone—Dyspepsia—Epirubicin—prostate cancer	1.97e-05	0.000129	CcSEcCtD
Hydromorphone—Diarrhoea—Prednisone—prostate cancer	1.96e-05	0.000129	CcSEcCtD
Hydromorphone—Decreased appetite—Epirubicin—prostate cancer	1.94e-05	0.000128	CcSEcCtD
Hydromorphone—Hypotension—Doxorubicin—prostate cancer	1.93e-05	0.000127	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Epirubicin—prostate cancer	1.93e-05	0.000127	CcSEcCtD
Hydromorphone—Fatigue—Epirubicin—prostate cancer	1.93e-05	0.000127	CcSEcCtD
Hydromorphone—Constipation—Epirubicin—prostate cancer	1.91e-05	0.000126	CcSEcCtD
Hydromorphone—Pain—Epirubicin—prostate cancer	1.91e-05	0.000126	CcSEcCtD
Hydromorphone—Nausea—Capecitabine—prostate cancer	1.91e-05	0.000125	CcSEcCtD
Hydromorphone—Dizziness—Prednisone—prostate cancer	1.89e-05	0.000124	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.88e-05	0.000124	CcSEcCtD
Hydromorphone—Insomnia—Doxorubicin—prostate cancer	1.87e-05	0.000123	CcSEcCtD
Hydromorphone—Paraesthesia—Doxorubicin—prostate cancer	1.86e-05	0.000122	CcSEcCtD
Hydromorphone—Dyspnoea—Doxorubicin—prostate cancer	1.84e-05	0.000121	CcSEcCtD
Hydromorphone—Feeling abnormal—Epirubicin—prostate cancer	1.84e-05	0.000121	CcSEcCtD
Hydromorphone—Somnolence—Doxorubicin—prostate cancer	1.84e-05	0.000121	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Epirubicin—prostate cancer	1.83e-05	0.00012	CcSEcCtD
Hydromorphone—Dyspepsia—Doxorubicin—prostate cancer	1.82e-05	0.00012	CcSEcCtD
Hydromorphone—Vomiting—Prednisone—prostate cancer	1.82e-05	0.00012	CcSEcCtD
Hydromorphone—Rash—Prednisone—prostate cancer	1.8e-05	0.000119	CcSEcCtD
Hydromorphone—Dermatitis—Prednisone—prostate cancer	1.8e-05	0.000118	CcSEcCtD
Hydromorphone—Decreased appetite—Doxorubicin—prostate cancer	1.8e-05	0.000118	CcSEcCtD
Hydromorphone—Headache—Prednisone—prostate cancer	1.79e-05	0.000118	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.79e-05	0.000117	CcSEcCtD
Hydromorphone—Fatigue—Doxorubicin—prostate cancer	1.78e-05	0.000117	CcSEcCtD
Hydromorphone—Urticaria—Epirubicin—prostate cancer	1.78e-05	0.000117	CcSEcCtD
Hydromorphone—Constipation—Doxorubicin—prostate cancer	1.77e-05	0.000116	CcSEcCtD
Hydromorphone—Pain—Doxorubicin—prostate cancer	1.77e-05	0.000116	CcSEcCtD
Hydromorphone—Abdominal pain—Epirubicin—prostate cancer	1.77e-05	0.000116	CcSEcCtD
Hydromorphone—Body temperature increased—Epirubicin—prostate cancer	1.77e-05	0.000116	CcSEcCtD
Hydromorphone—Feeling abnormal—Doxorubicin—prostate cancer	1.7e-05	0.000112	CcSEcCtD
Hydromorphone—Nausea—Prednisone—prostate cancer	1.7e-05	0.000112	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Doxorubicin—prostate cancer	1.69e-05	0.000111	CcSEcCtD
Hydromorphone—Hypersensitivity—Epirubicin—prostate cancer	1.65e-05	0.000108	CcSEcCtD
Hydromorphone—Urticaria—Doxorubicin—prostate cancer	1.64e-05	0.000108	CcSEcCtD
Hydromorphone—Body temperature increased—Doxorubicin—prostate cancer	1.64e-05	0.000108	CcSEcCtD
Hydromorphone—Abdominal pain—Doxorubicin—prostate cancer	1.64e-05	0.000108	CcSEcCtD
Hydromorphone—Asthenia—Epirubicin—prostate cancer	1.6e-05	0.000105	CcSEcCtD
Hydromorphone—Pruritus—Epirubicin—prostate cancer	1.58e-05	0.000104	CcSEcCtD
Hydromorphone—Diarrhoea—Epirubicin—prostate cancer	1.53e-05	0.000101	CcSEcCtD
Hydromorphone—Hypersensitivity—Doxorubicin—prostate cancer	1.52e-05	0.0001	CcSEcCtD
Hydromorphone—Asthenia—Doxorubicin—prostate cancer	1.48e-05	9.76e-05	CcSEcCtD
Hydromorphone—Dizziness—Epirubicin—prostate cancer	1.48e-05	9.72e-05	CcSEcCtD
Hydromorphone—Pruritus—Doxorubicin—prostate cancer	1.46e-05	9.62e-05	CcSEcCtD
Hydromorphone—Vomiting—Epirubicin—prostate cancer	1.42e-05	9.35e-05	CcSEcCtD
Hydromorphone—Diarrhoea—Doxorubicin—prostate cancer	1.42e-05	9.31e-05	CcSEcCtD
Hydromorphone—Rash—Epirubicin—prostate cancer	1.41e-05	9.27e-05	CcSEcCtD
Hydromorphone—Dermatitis—Epirubicin—prostate cancer	1.41e-05	9.26e-05	CcSEcCtD
Hydromorphone—Headache—Epirubicin—prostate cancer	1.4e-05	9.21e-05	CcSEcCtD
Hydromorphone—Dizziness—Doxorubicin—prostate cancer	1.37e-05	9e-05	CcSEcCtD
Hydromorphone—Nausea—Epirubicin—prostate cancer	1.33e-05	8.73e-05	CcSEcCtD
Hydromorphone—Vomiting—Doxorubicin—prostate cancer	1.32e-05	8.65e-05	CcSEcCtD
Hydromorphone—Rash—Doxorubicin—prostate cancer	1.3e-05	8.58e-05	CcSEcCtD
Hydromorphone—Dermatitis—Doxorubicin—prostate cancer	1.3e-05	8.57e-05	CcSEcCtD
Hydromorphone—Headache—Doxorubicin—prostate cancer	1.3e-05	8.52e-05	CcSEcCtD
Hydromorphone—Nausea—Doxorubicin—prostate cancer	1.23e-05	8.08e-05	CcSEcCtD
Hydromorphone—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	3.46e-06	3.85e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	3.45e-06	3.84e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—KRAS—prostate cancer	3.42e-06	3.8e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—NOS3—prostate cancer	3.41e-06	3.79e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.4e-06	3.78e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA4—prostate cancer	3.4e-06	3.78e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NCOA2—prostate cancer	3.38e-06	3.76e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—APC—prostate cancer	3.35e-06	3.73e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	3.35e-06	3.73e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NCOA2—prostate cancer	3.35e-06	3.73e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CG—prostate cancer	3.34e-06	3.72e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—FGF2—prostate cancer	3.34e-06	3.72e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CXCL8—prostate cancer	3.33e-06	3.71e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EGF—prostate cancer	3.32e-06	3.69e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IRS1—prostate cancer	3.32e-06	3.69e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA2—prostate cancer	3.31e-06	3.69e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—NOS3—prostate cancer	3.29e-06	3.67e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.27e-06	3.64e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ABCG5—prostate cancer	3.27e-06	3.64e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CDKN1B—prostate cancer	3.26e-06	3.62e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—SLC5A5—prostate cancer	3.23e-06	3.59e-05	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—AKT1—prostate cancer	3.22e-06	3.58e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—GSK3B—prostate cancer	3.22e-06	3.58e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—JAK2—prostate cancer	3.2e-06	3.56e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—SLC5A5—prostate cancer	3.2e-06	3.56e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTA1—prostate cancer	3.2e-06	3.56e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CASP3—prostate cancer	3.19e-06	3.55e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IL2—prostate cancer	3.19e-06	3.54e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—INS—prostate cancer	3.18e-06	3.53e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—IL6—prostate cancer	3.17e-06	3.53e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—INS—prostate cancer	3.17e-06	3.52e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTO1—prostate cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NAT2—prostate cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP2E1—prostate cancer	3.15e-06	3.51e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PIK3CB—prostate cancer	3.14e-06	3.5e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	3.14e-06	3.49e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MDM2—prostate cancer	3.13e-06	3.48e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP2E1—prostate cancer	3.12e-06	3.48e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NQO1—prostate cancer	3.12e-06	3.47e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PTGS2—prostate cancer	3.11e-06	3.47e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CREBBP—prostate cancer	3.11e-06	3.46e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CCND1—prostate cancer	3.11e-06	3.46e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—CREBBP—prostate cancer	3.1e-06	3.45e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NQO1—prostate cancer	3.09e-06	3.44e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—ERBB2—prostate cancer	3.08e-06	3.43e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CTNNB1—prostate cancer	3.08e-06	3.42e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IGF1—prostate cancer	3.07e-06	3.42e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—TH—prostate cancer	3.07e-06	3.42e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—EGFR—prostate cancer	3.06e-06	3.4e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—TH—prostate cancer	3.04e-06	3.39e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	3.04e-06	3.38e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP3A4—prostate cancer	3.04e-06	3.38e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—LRP2—prostate cancer	3.03e-06	3.37e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.03e-06	3.37e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PLCB2—prostate cancer	3.03e-06	3.37e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.03e-06	3.37e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MMP9—prostate cancer	3.01e-06	3.35e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP3A4—prostate cancer	3.01e-06	3.35e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CDKN1A—prostate cancer	3e-06	3.34e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3e-06	3.34e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—PTEN—prostate cancer	3e-06	3.34e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.99e-06	3.32e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—P4HB—prostate cancer	2.97e-06	3.31e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	2.97e-06	3.3e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.96e-06	3.3e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	2.95e-06	3.28e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CD—prostate cancer	2.94e-06	3.27e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—AKT1—prostate cancer	2.92e-06	3.25e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CXCL8—prostate cancer	2.92e-06	3.25e-05	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	2.92e-06	3.25e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	2.92e-06	3.25e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GGT1—prostate cancer	2.89e-06	3.22e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.89e-06	3.22e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—KRAS—prostate cancer	2.89e-06	3.21e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GGT1—prostate cancer	2.87e-06	3.19e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—EP300—prostate cancer	2.86e-06	3.18e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	2.85e-06	3.18e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NCOA1—prostate cancer	2.85e-06	3.17e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NCOA1—prostate cancer	2.83e-06	3.14e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—FGF2—prostate cancer	2.82e-06	3.14e-05	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	2.82e-06	3.14e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.82e-06	3.14e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.81e-06	3.13e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CASP3—prostate cancer	2.8e-06	3.11e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL2—prostate cancer	2.79e-06	3.11e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.78e-06	3.1e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—NOS3—prostate cancer	2.78e-06	3.1e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—SRC—prostate cancer	2.78e-06	3.09e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—IL6—prostate cancer	2.78e-06	3.09e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—NOS3—prostate cancer	2.78e-06	3.09e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—MED12—prostate cancer	2.77e-06	3.09e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GNG5—prostate cancer	2.75e-06	3.06e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CCND1—prostate cancer	2.72e-06	3.03e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PTEN—prostate cancer	2.72e-06	3.02e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—RXRA—prostate cancer	2.71e-06	3.02e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—VEGFA—prostate cancer	2.71e-06	3.01e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—JAK2—prostate cancer	2.71e-06	3.01e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	2.7e-06	3e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—RXRA—prostate cancer	2.69e-06	2.99e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—STAT3—prostate cancer	2.68e-06	2.98e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	2.65e-06	2.95e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NCOA3—prostate cancer	2.65e-06	2.95e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MMP9—prostate cancer	2.64e-06	2.94e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MDM2—prostate cancer	2.64e-06	2.94e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	2.63e-06	2.93e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PTEN—prostate cancer	2.63e-06	2.92e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.61e-06	2.91e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—COMT—prostate cancer	2.61e-06	2.91e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—ERBB2—prostate cancer	2.6e-06	2.9e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GSTP1—prostate cancer	2.6e-06	2.89e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—EP300—prostate cancer	2.59e-06	2.88e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—COMT—prostate cancer	2.59e-06	2.88e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GSTP1—prostate cancer	2.58e-06	2.87e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	2.57e-06	2.86e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—AKT1—prostate cancer	2.56e-06	2.85e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CB—prostate cancer	2.56e-06	2.85e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ITPR1—prostate cancer	2.56e-06	2.85e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PTGS2—prostate cancer	2.54e-06	2.83e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ITPR1—prostate cancer	2.54e-06	2.82e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—HPGDS—prostate cancer	2.53e-06	2.81e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.51e-06	2.8e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—EP300—prostate cancer	2.51e-06	2.79e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.49e-06	2.77e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MYC—prostate cancer	2.49e-06	2.77e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TGFB1—prostate cancer	2.48e-06	2.77e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CXCL8—prostate cancer	2.47e-06	2.75e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTT1—prostate cancer	2.45e-06	2.73e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ACHE—prostate cancer	2.45e-06	2.73e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—SRC—prostate cancer	2.44e-06	2.71e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—EGFR—prostate cancer	2.44e-06	2.71e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.42e-06	2.7e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—TYMS—prostate cancer	2.42e-06	2.69e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	2.41e-06	2.68e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—TYMS—prostate cancer	2.4e-06	2.67e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GSTM1—prostate cancer	2.39e-06	2.66e-05	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	2.39e-06	2.66e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—VEGFA—prostate cancer	2.37e-06	2.64e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GSTM1—prostate cancer	2.37e-06	2.63e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CASP3—prostate cancer	2.36e-06	2.63e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL2—prostate cancer	2.36e-06	2.63e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.36e-06	2.62e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—STAT3—prostate cancer	2.35e-06	2.62e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—IL6—prostate cancer	2.35e-06	2.61e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PRKACB—prostate cancer	2.34e-06	2.61e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—LPL—prostate cancer	2.34e-06	2.61e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—LPL—prostate cancer	2.32e-06	2.59e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.32e-06	2.58e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—KRAS—prostate cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CCND1—prostate cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	2.28e-06	2.54e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.26e-06	2.52e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ERCC2—prostate cancer	2.25e-06	2.5e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.24e-06	2.5e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MMP9—prostate cancer	2.23e-06	2.49e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ERCC2—prostate cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PTEN—prostate cancer	2.22e-06	2.47e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PTEN—prostate cancer	2.21e-06	2.46e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NCOA2—prostate cancer	2.21e-06	2.46e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MYC—prostate cancer	2.18e-06	2.43e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TGFB1—prostate cancer	2.18e-06	2.42e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—AKT1—prostate cancer	2.17e-06	2.41e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—EGFR—prostate cancer	2.14e-06	2.38e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EP300—prostate cancer	2.12e-06	2.36e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	2.11e-06	2.35e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—EP300—prostate cancer	2.11e-06	2.35e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—MTHFR—prostate cancer	2.11e-06	2.35e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.11e-06	2.35e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—MTHFR—prostate cancer	2.09e-06	2.33e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PPARA—prostate cancer	2.07e-06	2.3e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.06e-06	2.29e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—SRC—prostate cancer	2.06e-06	2.29e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PPARA—prostate cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TP53—prostate cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NQO1—prostate cancer	2.04e-06	2.27e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—KRAS—prostate cancer	2.02e-06	2.25e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—TH—prostate cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—VEGFA—prostate cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—STAT3—prostate cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.95e-06	2.17e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CAV1—prostate cancer	1.95e-06	2.17e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CAV1—prostate cancer	1.93e-06	2.15e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PIK3CA—prostate cancer	1.92e-06	2.13e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GGT1—prostate cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IL6—prostate cancer	1.87e-06	2.08e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NCOA1—prostate cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	1.85e-06	2.06e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MYC—prostate cancer	1.85e-06	2.05e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.84e-06	2.05e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TGFB1—prostate cancer	1.84e-06	2.05e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EGFR—prostate cancer	1.81e-06	2.01e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TP53—prostate cancer	1.79e-06	2e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.77e-06	1.97e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—RXRA—prostate cancer	1.77e-06	1.97e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.76e-06	1.96e-05	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—AKT1—prostate cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—COMT—prostate cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—KRAS—prostate cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTP1—prostate cancer	1.7e-06	1.89e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—INS—prostate cancer	1.68e-06	1.87e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ITPR1—prostate cancer	1.67e-06	1.86e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—INS—prostate cancer	1.66e-06	1.85e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CREBBP—prostate cancer	1.64e-06	1.83e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL6—prostate cancer	1.64e-06	1.83e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CREBBP—prostate cancer	1.63e-06	1.81e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—TYMS—prostate cancer	1.58e-06	1.76e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	1.57e-06	1.74e-05	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—AKT1—prostate cancer	1.57e-06	1.74e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PIK3CA—prostate cancer	1.56e-06	1.74e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTM1—prostate cancer	1.56e-06	1.74e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.56e-06	1.74e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—LPL—prostate cancer	1.53e-06	1.71e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TP53—prostate cancer	1.52e-06	1.69e-05	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—AKT1—prostate cancer	1.51e-06	1.69e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.48e-06	1.65e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NOS3—prostate cancer	1.47e-06	1.64e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ERCC2—prostate cancer	1.47e-06	1.63e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NOS3—prostate cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL6—prostate cancer	1.39e-06	1.54e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—MTHFR—prostate cancer	1.38e-06	1.54e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.36e-06	1.51e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PPARA—prostate cancer	1.35e-06	1.51e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.35e-06	1.5e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PTGS2—prostate cancer	1.35e-06	1.5e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PTGS2—prostate cancer	1.33e-06	1.49e-05	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—AKT1—prostate cancer	1.28e-06	1.42e-05	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—AKT1—prostate cancer	1.28e-06	1.42e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CAV1—prostate cancer	1.27e-06	1.42e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PTEN—prostate cancer	1.17e-06	1.31e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PTEN—prostate cancer	1.16e-06	1.3e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.16e-06	1.29e-05	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—EP300—prostate cancer	1.12e-06	1.25e-05	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—EP300—prostate cancer	1.11e-06	1.24e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—INS—prostate cancer	1.1e-06	1.22e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CREBBP—prostate cancer	1.08e-06	1.2e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.02e-06	1.13e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NOS3—prostate cancer	9.63e-07	1.07e-05	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CB—prostate cancer	8.89e-07	9.89e-06	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PTGS2—prostate cancer	8.8e-07	9.8e-06	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PIK3CA—prostate cancer	8.28e-07	9.22e-06	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PIK3CA—prostate cancer	8.21e-07	9.14e-06	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PTEN—prostate cancer	7.68e-07	8.54e-06	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—EP300—prostate cancer	7.32e-07	8.15e-06	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—AKT1—prostate cancer	6.77e-07	7.53e-06	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—AKT1—prostate cancer	6.71e-07	7.47e-06	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.42e-07	6.03e-06	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—AKT1—prostate cancer	4.42e-07	4.92e-06	CbGpPWpGaD
